Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents - Results of the APOLLO study

被引：0
|
作者：
Bretzel, Reinhard G.
Linn, Thomas
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：A76 / A76
页数：1
相关论文
共 50 条
  • [21] Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial (vol 371, pg 1073, 2008)
    Bretzel, R. G.
    Nuber, U.
    Landgraf, W.
    Owens, D. R.
    Bradley, C.
    Linn, T.
    LANCET, 2008, 372 (9640): : 718 - 718
  • [22] Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
    Tinahones, F. J.
    Gross, J. L.
    Onaca, A.
    Cleall, S.
    Rodriguez, A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 963 - 970
  • [23] Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents
    Wolffenbuttel, B. H. R.
    Klaff, L. J.
    Bhushan, R.
    Fahrbach, J. L.
    Jiang, H.
    Martin, S.
    DIABETIC MEDICINE, 2009, 26 (11) : 1147 - 1155
  • [24] Effects of 1, 2, or 3 Prandial Injections of Insulin Glulisine on Glycemic Control in Type 2 Diabetes Patients an Insulin Glargine and Oral Drugs
    Davidson, Mayer B.
    Raskin, Philip
    Tanenberg, Robert
    Vlajnic, Aleksandra
    Hollander, Priscilla
    DIABETES, 2009, 58 : A132 - A132
  • [25] Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
    Bergenstal, R. M.
    Lunt, H.
    Franek, E.
    Travert, F.
    Mou, J.
    Qu, Y.
    Antalis, C. J.
    Hartman, M. L.
    Rosilio, M.
    Jacober, S. J.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1081 - 1088
  • [26] Treatment to target study:: Feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus®) or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents
    Rosenstock, J
    Riddle, M
    Dailey, G
    Gerich, J
    Mecca, T
    Wilson, C
    Bugos, C
    DIABETES, 2001, 50 : A129 - A130
  • [27] Feasibility of improved glycemic control with insulin detemir and insulin glargine in combination with oral agents in insulin naive patients with type 2 diabetes
    Rosenstock, J
    Larsen, JJ
    Draeger, E
    Kristensen, HS
    Davies, M
    DIABETES, 2004, 53 : A145 - A145
  • [28] Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control A Randomized Trial
    Esposito, Katherine
    Ciotola, Miryam
    Maiorino, Maria Ida
    Gualdiero, Roberto
    Schisano, Bruno
    Ceriello, Antonio
    Beneduce, Flora
    Feola, Giovanni
    Giugliano, Dario
    ANNALS OF INTERNAL MEDICINE, 2008, 149 (08) : 531 - 103
  • [29] Optimal insulin treatment for patients with type 2 diabetes - Basal or prandial insulin supplementation?
    Jermendy, Gyorgy
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 : S20 - S29
  • [30] Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
    Rosenstock, Julio
    Fonseca, Vivian A.
    Gross, Jorge L.
    Ratner, Robert E.
    Ahren, Bo
    Chow, Francis C. C.
    Yang, Fred
    Miller, Diane
    Johnson, Susan L.
    Stewart, Murray W.
    Leiter, Lawrence A.
    DIABETES CARE, 2014, 37 (08) : 2317 - 2325
12345